?? Missed #2024SPS in San Diego? Don’t worry—you can still access the cutting-edge insights and industry updates shared at our Annual Meeting! ?? Explore our SPS Annual Meeting: On-Demand and On-Demand+ Posters, available online. ?? Flexible learning at your own pace on any device; access is one year from the purchase date. ?? NEW pricing for Members, Nonmembers, Students, and Retired individuals making it more accessible than ever! ?? Don’t miss this opportunity to learn and expand your expertise. Get started today! https://ow.ly/jWAa50UeaxG #safetypharmacology #drugdiscovery #NAMs #3Rs
Safety Pharmacology Society
研究服务
Reston，Virginia 1,217 位关注者
Providing guidance and answers to critical questions that matter to patients, regulators, and scientists
关于我们
The Safety Pharmacology Society is a nonprofit organization that promotes knowledge, development, application, and training in safety pharmacology—a distinct scientific discipline that integrates the best practices of pharmacology, physiology and toxicology. Vision The Society will lead the global safety pharmacology community in the development and safe medical use of biologically active molecular entities. We will achieve this vision by bridging across disciplines to predict, identify, characterize, monitor, and mitigate potentially undesirable pharmacodynamic activities in nonclinical studies and guiding their translation into clinical trials and beyond, to benefit all patients. Purpose: Safety pharmacology leaders providing guidance and answers to critical questions that matter to patients, regulators, and scientists.
- 网站
-
https://safetypharmacology.org/
Safety Pharmacology Society的外部链接
- 所属行业
- 研究服务
- 规模
- 2-10 人
- 总部
- Reston，Virginia
- 类型
- 非营利机构
- 创立
- 2000
地点
-
主要
获取路线
11190 Sunrise Valley Drive, Suite 300
US，Virginia，Reston，20191
Safety Pharmacology Society员工
动态
-
Summer 2025 Cardiovascular Discovery Internship at BMS. See details below!
We are looking for a passionate graduate student (Bioinformatics/CompBio) to join our summer internship program to build machine learning models using real-world multi-modal data (genetics, clinical, imaging) to enable cardiovascular drug discovery! Come join us! Please feel free to share with anyone who may be interested: https://lnkd.in/gEqUVYxj
-
Registration closes in one day! Join us this week for our next webinar now featuring two speakers: Andy Makin, MSc and Szczepan Baran, VMD. Details below:
??Announcing our next webinar, "What's Hot in the Minipig World" with Andy Makin, MSc and Szczepan Baran, VMD! Join us on November 21 at 8:00 AM PST / 11:00 AM EST / 17:00 CET to explore the state of the art in the minipig world and real-world examples. ??? Register and share with colleagues ??https://ow.ly/9E0e50TVWAF #Minipigs #PreclinicalResearch #safetypharmacology #drugdevelopment
-
-
Sharing "How to get into a PhD programme in Oxford" (see below for full details) - thanks for the insights Blanca! Click through to learn more.
Professor of Computational Medicine, Research & Innovation, Advisor & Consultant, Training & Coaching
?? How to get into a PhD programme in Oxford (called DPhil) ?? Deadline: December 3rd, 2024. ?? Important to get a scholarship. Three main routes: 1???? Through a departmental programme, for example, DPhil in Computer Science. Within the application, you will be naming one or more possible supervisors. They will be screening your application in terms of track record and also how your research interests align with theirs. It is important to read the supervisors latest papers before applying to work with them (and before contacting them). This is typically 3/3.5 years. Some links: DPhil in Computer Science, Department of Computer Science, University of Oxford: https://lnkd.in/d5QVZ6a6 For other programmes University of Oxford Course listing: https://lnkd.in/ewgc5xt8 2????Through a Centre of Doctoral Training (CDT) or Doctoral Training Programme (DTP). Here you do not name a supervisor. You would be admitted to a programme and you will choose rotations and supervisors in the first year. This is typically 4 years. For example, Healthcare Data Science, https://lnkd.in/eixeApkM Oxford Interdisciplinary Bioscience https://lnkd.in/ebsbuxJd 3?? ??Through specific scholarships (for example in collaboration with industry. This is similar to the first route but you apply to work on a specific project (still within a DPhil programme). ?? ?? Opportunity with us in Computational Cardiology in collaboration with AstraZeneca, on 'Strategies for novel cardiomyopathy treatments from organoids-informed computational multiscale modelling and simulation': https://lnkd.in/e8Hs-cD2 You apply through the DPhil in Computer Science programme, but selecting this particular project: https://lnkd.in/d5QVZ6a6
-
-
??Announcing our next webinar, "What's Hot in the Minipig World" with Andy Makin, MSc and Szczepan Baran, VMD! Join us on November 21 at 8:00 AM PST / 11:00 AM EST / 17:00 CET to explore the state of the art in the minipig world and real-world examples. ??? Register and share with colleagues ??https://ow.ly/9E0e50TVWAF #Minipigs #PreclinicalResearch #safetypharmacology #drugdevelopment
-
-
??Attention all college students or recent graduates in the STEM field! FDA's (Office of New Drugs) Summer ORISE program is accepting applications through April 18, 2025!
? Are you a college student or recent graduate in the STEM field? ? Are you also interested in participating in mentor-led research projects to gain hands-on experience during the summer? ?? FDA's Office of New Drugs (OND)'s Summer ORISE program may be the program for you. ?? Read more about OND’s summer regulatory research projects and the impact they have had: https://lnkd.in/gt5uWn47
-
Congratulations to the authors and SPS Members involved in the publication "Cross clinical-experimental-computational qualification of?in silico?drug trials on human cardiac purkinje cells for proarrhythmia risk prediction" in Frontiers in Toxicology. It was recognized during the 2024 SPS Annual Meeting as the selection for the "Translational Research Publication Award." The Translational Safety Pharmacology Publication Award is given for research based on the evaluation of the translation from?in silico?to?in vitro,?in vitro?to?in vivo, or?in silico,?in vitro?and/or?in vivo?to human. Read Here?? https://lnkd.in/g4bR8XZt
Frontiers | Cross clinical-experimental-computational qualification of in silico drug trials on human cardiac purkinje cells for proarrhythmia risk prediction
frontiersin.org
-
Congratulations to the authors and SPS Members involved in the publication "Time Is a Critical Factor When Evaluating Oligonucleotide Therapeutics in hERG Assays" in Nucleic Acid Therapeutics. It was recognized during the 2024 SPS Annual Meeting as the selection for the "Technological Innovation Publication Award." The Technological Innovation Publication Award is given for research based on a ‘breakthrough’ technology that could potentially enhance/revolutionize the way we are doing an aspect of safety pharmacology. Read Here??https://lnkd.in/gxGhjwrU
Time Is a Critical Factor When Evaluating Oligonucleotide Therapeutics in hERG Assays | Nucleic Acid Therapeutics
liebertpub.com
-
Congratulations to the authors and SPS Members involved in the publication "The state?of?the?art in secondary pharmacology and its impact on the safety of new medicines," in the Nature Reviews Drug Discovery. It was recognized during the 2024 SPS Annual Meeting as the selection for the "Most Impactful Publication Award." The Most Impactful Publication Award is given by SPS to recognize an exceptional, recently published paper that impacts scientific advancement in safety pharmacology.
Earlier this year, the IQ Consortium's In Vitro Secondary Pharmacology Profiling Working Group published their article, "The state?of?the?art in secondary pharmacology and its impact on the safety of new medicines," in the Nature Reviews Drug Discovery. This publication has recently been honored by the Safety Pharmacology Society as the "Most Impactful Safety Pharmacology Publication of the Year." Congratulations to the authors! Richard Brennan, Steve Jenkinson, Andrew Brown, Annie Delaunois, Berengere Dumotier, Malar Pannirselvam, Mohan Rao, PhD., Lyn Rosenbrier Ribeiro, Friedemann Schmidt, Alicia Sibony, Yoav Timsit, Vicencia Toledo Sales, Duncan Armstrong, Armando Lagrutta, Scott Mittelstadt, Russell Naven, Ravikumar Peri, Sonia Roberts, James Vergis, and Jean-Pierre Valentin #IQpublication #IQconsortium #secondarypharmacology #IQDruSafe
The state of the art in secondary pharmacology and its impact on the safety of new medicines - Nature Reviews Drug Discovery
nature.com
-
Re-sharing for students looking for funded PhD opportunities with October 2025 start dates. Details are also here: https://lnkd.in/euEvHHtf
AstraZeneca and the University of Cambridge have 11 funded PhD opportunities which will be available for October 2025 starts. Please check out the link below to see details of the projects that will be available: https://lnkd.in/euEvHHtf Application links will be posted here when available: https://lnkd.in/ewUgmujc Jacqui Hall, FRSBMeghana PatelSteve Rees OBE